Page 24 - Sofinnova Partners News Today

/PRNewswire/ -- Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment...

DGAP-News: iOmx Therapeutics AG / Key word(s): Conference/Scientific publication iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022 07.04.2022

NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 21st Annual Needham Virtual Healthcare Conference at 10:15 A.M. EST on April 14,...

PARIS, FRANCE / ACCESSWIRE / April 7, 2022 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of heart failure patients

LimFlow announced today that it closed an oversubscribed Series D financing round worth proceeds of $40 million (€36 million).

Funds to Support Completion of Clinical Program Through Commercialization of Novel Device Designed to Prevent Amputations in Patients with Chronic Limb-Threatening Ischemia LimFlow SA, a pioneer

/PRNewswire/ -- Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces the publication...

Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced it has been granted

MILAN, ITALY / ACCESSWIRE / March 31, 2022 / AAVantgarde Bio, a Milan-based biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV)

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability.